What is the address of DR. LAURENS CLAEYS - NEFROLOGIE?

The registered office of DR. LAURENS CLAEYS - NEFROLOGIE is located at Voordelaan 24, 9831 Sint-Martens-Latem.

Is DR. LAURENS CLAEYS - NEFROLOGIE still active?

Yes. According to the CBE (16 September 2026) DR. LAURENS CLAEYS - NEFROLOGIE is active, legal situation “Normale toestand”, started on 16 April 2021.

Is DR. LAURENS CLAEYS - NEFROLOGIE registered on Peppol?

No, DR. LAURENS CLAEYS - NEFROLOGIE is currently not registered on the Peppol network.

What is the enterprise number of DR. LAURENS CLAEYS - NEFROLOGIE?

The enterprise number of DR. LAURENS CLAEYS - NEFROLOGIE is BE0766816474.

When was DR. LAURENS CLAEYS - NEFROLOGIE founded?

DR. LAURENS CLAEYS - NEFROLOGIE was founded on 16 April 2021.

Who are the directors of DR. LAURENS CLAEYS - NEFROLOGIE?

According to the 2026 annual accounts, the directors of DR. LAURENS CLAEYS - NEFROLOGIE are: Laurens Claeys.

Is DR. LAURENS CLAEYS - NEFROLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 April 2021; 5 annual accounts filed, latest fiscal year 2026; 1 directors known from the annual account.

How much profit did DR. LAURENS CLAEYS - NEFROLOGIE make in 2026?

DR. LAURENS CLAEYS - NEFROLOGIE posted a profit after taxes of € 299,536 in financial year 2026.

What is the revenue of DR. LAURENS CLAEYS - NEFROLOGIE?

As a small company, DR. LAURENS CLAEYS - NEFROLOGIE is not required to publish revenue in its annual accounts. In financial year 2026, its added value was € 423,418.

DR. LAURENS CLAEYS - NEFROLOGIE (Private Limited)

Dossier DR. LAURENS CLAEYS - NEFROLOGIE, printed on 16 September 2026 from databakkes.be/en/0766816474/dr-laurens-claeys-nefrologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 60 % of short-term debt in 2026; threshold 65 %.
Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2026

DR. LAURENS CLAEYS - NEFROLOGIE from Sint-Martens-Latem, company number BE0766816474, closed financial year 2026 with a result of € 299,536 after tax. For that financial year DR. LAURENS CLAEYS - NEFROLOGIE recorded a gross margin of € 423,418 and equity of € 100. Compared with financial year 2025, the result moved from € 119,702 to € 299,536. Profitable, and profit is growing. The buffer shrank hard: equity is 98 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 22, 2026.

What it is worth Shrank hard

€ 100

▼ 98% vs 2025

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 299,536

▲ 150% vs 2025

Profit after tax over the fiscal year.

Cash in the bank

€ 122,455

▲ 88% vs 2025

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 304,536 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2026

Vehicles and equipment

€ 63,709

▼ 27% vs 2025

Book value of vehicles, furniture and equipment.

Debts at end 2026

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 44,741

▼ 27% vs 2025

€ 17,490 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 15,027

▼ 9% vs 2025

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 45,680

▲ 21% vs 2025

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	2026	Change 2025 → 2026
Gross margin	€ 62,637 Gross margin 2023: € 62,637 First fiscal year in the series	€ 59,741 Gross margin 2024: € 59,741 ▼ 5% vs 2023 (€ 62,637) Unfavourable step	€ 181,488 Gross margin 2025: € 181,488 ▲ 204% vs 2024 (€ 59,741) Favourable step	€ 423,418 Gross margin 2026: € 423,418 ▲ 133% vs 2025 (€ 181,488) Favourable step	▲ 133%
Profit after taxes	€ 44,265 Profit after taxes 2023: € 44,265 First fiscal year in the series	€ 39,123 Profit after taxes 2024: € 39,123 ▼ 12% vs 2023 (€ 44,265) Unfavourable step	€ 119,702 Profit after taxes 2025: € 119,702 ▲ 206% vs 2024 (€ 39,123) Favourable step	€ 299,536 Profit after taxes 2026: € 299,536 ▲ 150% vs 2025 (€ 119,702) Favourable step	▲ 150%
Equity	€ 133,638 Equity 2023: € 133,638 First fiscal year in the series	€ 172,761 Equity 2024: € 172,761 ▲ 29% vs 2023 (€ 133,638) Favourable step	€ 5,100 Equity 2025: € 5,100 ▼ 97% vs 2024 (€ 172,761) Unfavourable step	€ 100 Equity 2026: € 100 ▼ 98% vs 2025 (€ 5,100) Unfavourable step	▼ 98%
Total debts	€ 7,571 Total debts 2023: € 7,571 First fiscal year in the series	€ 10,339 Total debts 2024: € 10,339 ▲ 37% vs 2023 (€ 7,571) Unfavourable step	€ 213,593 Total debts 2025: € 213,593 ▲ € 203,254 vs 2024 (€ 10,339) Unfavourable step	€ 364,304 Total debts 2026: € 364,304 ▲ 71% vs 2025 (€ 213,593) Unfavourable step	▲ 71%
Cash	€ 55,708 Cash 2023: € 55,708 First fiscal year in the series	€ 60,509 Cash 2024: € 60,509 ▲ 9% vs 2023 (€ 55,708) Favourable step	€ 64,986 Cash 2025: € 64,986 ▲ 7% vs 2024 (€ 60,509) Favourable step	€ 122,455 Cash 2026: € 122,455 ▲ 88% vs 2025 (€ 64,986) Favourable step	▲ 88%
Retained profit	€ 133,538 Retained profit 2023: € 133,538 First fiscal year in the series	€ 172,661 Retained profit 2024: € 172,661 ▲ 29% vs 2023 (€ 133,538) Favourable step	€ 5,000 Retained profit 2025: € 5,000 ▼ 97% vs 2024 (€ 172,661) Unfavourable step	€ 0 Retained profit 2026: € 0 ▼ 100% vs 2025 (€ 5,000) Unfavourable step	▼ 100%
Dividend	€ 0 Dividend 2023: € 0 First fiscal year in the series	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 287,364 Dividend 2025: € 287,364 Unchanged (€ 0) Unchanged	€ 304,536 Dividend 2026: € 304,536 ▲ 6% vs 2025 (€ 287,364) Unchanged	▲ 6%
Bank debt	€ 0 Bank debt 2023: € 0 First fiscal year in the series	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 61,708 Bank debt 2025: € 61,708 Unchanged (€ 0) Unfavourable step	€ 44,741 Bank debt 2026: € 44,741 ▼ 27% vs 2025 (€ 61,708) Favourable step	▼ 27%
Balance sheet total	€ 141,209 Balance sheet total 2023: € 141,209 First fiscal year in the series	€ 183,101 Balance sheet total 2024: € 183,101 ▲ 30% vs 2023 (€ 141,209) Unchanged	€ 218,693 Balance sheet total 2025: € 218,693 ▲ 19% vs 2024 (€ 183,101) Unchanged	€ 364,404 Balance sheet total 2026: € 364,404 ▲ 67% vs 2025 (€ 218,693) Unchanged	▲ 67%

Key figures of DR. LAURENS CLAEYS - NEFROLOGIE, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 30 November 2027.

What happened to DR. LAURENS CLAEYS - NEFROLOGIE?

What happened at DR. LAURENS CLAEYS - NEFROLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 22, 2026 New annual accounts for financial year 2026: profit of € 299,536 (▲ 150% vs 2025). Source: NBB ↗
Apr 16, 2021 New establishment in Sint-Martens-Latem. KBO
2021 Laurens Claeys became a director. NBB
Apr 16, 2021 Start of the company according to the CBE. KBO

In short

From € 44,265 profit in 2023 to € 299,536 profit in 2026.

Paid € 161,192 in corporate taxes since 2023.

Best year ever: 2026, with € 299,536 profit.

Paid out € 591,900 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. LAURENS CLAEYS - NEFROLOGIE? We notify you, reason included.

Follow DR. LAURENS CLAEYS - NEFROLOGIE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Laurens Claeys

DR. LAURENS CLAEYS - NEFROLOGIE

Behind DR. LAURENS CLAEYS - NEFROLOGIE is Laurens Claeys.

See the full network in the app

Directors

According to the 2026 annual accounts

Laurens Claeys

Director

since 2021

Establishments

Establishment units

Physical locations of this company

Registered office

Voordelaan 24

9831 Sint-Martens-Latem

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0766.816.474
VAT number: BE 0766.816.474
Registered office: Voordelaan 24, 9831 Sint-Martens-Latem
Names & denominations: DR. LAURENS CLAEYS - NEFROLOGIE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 16 April 2021
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗